文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

通过皮下多次注射高剂量人重组白细胞介素-2（rIL-2），在体内增强C57BL/6小鼠脾淋巴细胞对同基因B-16黑色素瘤细胞的细胞毒性，并抑制人工转移。

In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).

作者信息

Saijo N, Ozaki A, Nakano H, Sakurai M, Takahashi H, Sasaki Y, Hoshi A

出版信息

J Cancer Res Clin Oncol. 1986;111(3):182-6. doi: 10.1007/BF00389231.

DOI:10.1007/BF00389231
PMID:3488319
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12252554/
Abstract

The cytotoxicity of spleen lymphocytes against YAC-1 cells, against syngeneic B-16 and F-10 melanoma cells was augmented not only by incubation of spleen lymphocytes with human recombinant interleukin-2 (rIL-2) in vitro, but also by injecting C57BL/6 mice with high dose rIL-2 for more than 3 consecutive days. In animals injected s.c. with multiple high dose rIL-2, the numbers of tumor nodules in the lung were significantly decreased 21 days after i.v. tumor inoculation. In addition, in these groups of animals no liver metastases were observed although liver metastases were detected in 6/11 control mice.

摘要

脾淋巴细胞对YAC-1细胞、同基因B-16和F-10黑色素瘤细胞的细胞毒性不仅通过在体外将脾淋巴细胞与人重组白细胞介素-2（rIL-2）孵育而增强，还通过连续3天以上给C57BL/6小鼠注射高剂量rIL-2来增强。在皮下注射多次高剂量rIL-2的动物中，静脉注射肿瘤接种21天后肺内肿瘤结节数量显著减少。此外，在这些动物组中未观察到肝转移，而在11只对照小鼠中有6只检测到肝转移。

相似文献

[1]
In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).

J Cancer Res Clin Oncol. 1986

[2]
[Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].

Gan To Kagaku Ryoho. 1986-4

[3]
Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GM1 antibody or anticancer agents.

J Cancer Res Clin Oncol. 1984

[4]
Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.

J Cancer Res Clin Oncol. 1991

[5]
Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent.

Jpn J Cancer Res. 1986-5

[6]
Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.

J Cancer Res Clin Oncol. 1993

[7]
Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.

J Cancer Res Clin Oncol. 1997

[8]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[9]
The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro.

Eur J Cancer Clin Oncol. 1988-6

[10]
Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray.

J Cancer Res Clin Oncol. 2003-1

引用本文的文献

[1]
Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.

Jpn J Cancer Res. 1988-1

[2]
Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Cancer Immunol Immunother. 1989

[3]
Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.

Jpn J Cancer Res. 1989-9

本文引用的文献

[1]
Analysis of natural killer activity and antibody-dependent cellular cytotoxicity in healthy volunteers and in patients with primary lung cancer and metastatic pulmonary tumors.

J Cancer Res Clin Oncol. 1982

[2]
Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF).

Cancer Immunol Immunother. 1982

[3]
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

Cancer Res. 1981-11

[4]
Analysis of metastatic spread and growth of tumor cells in mice with depressed natural killer activity by anti-asialo GM1 antibody or anticancer agents.

J Cancer Res Clin Oncol. 1984

[5]
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures.

Proc Natl Acad Sci U S A. 1984-6

[6]
In vivo administration of purified Jurkat-derived interleukin 2 in mice.

Cancer Res. 1984-4

[7]
Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.

Cancer Immunol Immunother. 1983

[8]
The fate of interleukin-2 after in vivo administration.

J Immunol. 1983-5

[9]
Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects.

Br J Cancer. 1983-1

[10]
Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.

Cancer. 1984-12-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索